Allergan, Inc. (Public, NYSE:AGN)

[Michael Scally MD]

Allergan, Inc. (Public, NYSE:AGN) Allergan
IR: http://www.allergan.com/investors/index.htm

GF: Allergan, Inc.: NYSE:AGN quotes & news - Google Finance
YF: AGN: Summary for Allergan, Inc. Common Stock- Yahoo! Finance
SA: Allergan Inc. (AGN) Stock - Seeking Alpha

SEC: EDGAR Search Results


Allergan is a global, technology-driven multi-specialty health care company pursuing therapeutic advances to help patients live life to their fullest potential. In making this commitment, we work to develop an unparalleled level of insight into patients' wants and needs — and into the priorities and concerns of the medical specialists who treat them. To this end, we employ more than 50 percent of our work force in either research and development (R&D) or sales, ensuring our efforts are focused on innovation and our customers.

Allergan's flagship franchises in eye care, neurosciences, medical dermatology and urologics are structured under the company's pharmaceutical business portfolio, Allergan Pharmaceuticals. This portfolio offers specialty physicians and their patients a wide range of treatments to help preserve and protect sight, reduce physical disability and enhance quality of life.

With the acquisition of Inamed Corporation in 2006, Allergan added breast aesthetics and dermal fillers to its business portfolio to create a world-leading medical aesthetics franchise. The acquisition also gained Allergan a leading product portfolio in obesity intervention that offers minimally invasive devices to help patients achieve sustained weight loss and reduce health risks associated with obesity. All of these products are now represented within the Allergan Medical corporate division.

With specialty product lines focused on high-growth markets, Allergan represents a new multi-specialty health care model for the future, where diversification and focus live together to offer physicians and patients best-in-class treatments and a robust pipeline for continuous innovation. Bolstered by an integrated R&D organization and global infrastructure, characteristics of some of the industry's largest pharmaceutical companies, Allergan also maintains a lean and efficient operation with solid growth prospects, like many smaller and more specialized organizations in the health care field. Allergan is large enough to command sufficient resources to address significant patient needs yet small enough for nimble execution. As we look to the future, we will continue to follow our R&D technologies into additional specialty areas and build a leadership presence of relevance to the doctors and patients we serve.


LAP-BAND® Adjustable Gastric Banding System
http://www.allergan.com/products/obesity_intervention/lap-band.htm

 

[Michael Scally MD]

Latisse For Androgenetic Alopecia (Male/Female Pattern Baldness)—AGN is running two large phase-2 trials, one for men and one for women: https://thinksteroids.com/community/posts/774168

 

[Michael Scally MD]

Allergan's BOTOX® Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury
BOTOX® injections can provide long-lasting bladder control for patients with neurogenic bladder
Allergan - Allergan's BOTOX® Receives A Positive Opinion in Fourteen European Countries for Urinary Incontinence in Patients with MS or Spinal Cord Injury

MARLOW, United Kingdom--(BUSINESS WIRE)-- Allergan is pleased to announce that BOTOX® (botulinum toxin type A) has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.1 This is an important step towards securing national licences in the 14 European countries involved in the Mutual Recognition Procedure and marks a key milestone in bringing this innovative treatment to patients suffering from urinary incontinence due to neurogenic detrusor overactivity. The positive opinion is specific for BOTOX® and is based on Allergan's successful global phase III programme.

Allergan's survival strategy: Botox everlasting
Botox is Allergan's edge over big pharmaceutical companies - Jun. 10, 2011

FORTUNE -- Big pharmaceutical companies aren't at a crossroads so much as on the edge of a cliff. Thanks to a special provision in patent laws for drugs, companies lose intellectual property protection on pharmaceuticals after 20 years. After that, exclusive rights to the drugs fall into an abyss of competition from other companies making much cheaper generic versions. The point at which pharma companies lose exclusive rights to their drugs is called the patent cliff.

Yet one company, Allergan (AGN, Fortune 500), has managed to steer clear of the edge. Most big, mainstream pharma companies are desperately working to develop new expensive drugs and filing lawsuits to extend patents on old ones. But to dodge that deadline, Allergan is using another strategy; let's call it the "stay small and make weird products" approach.

 

[Michael Scally MD]

Latisse For Androgenetic Alopecia (Male/Female Pattern Baldness)—AGN is running two large phase-2 trials, one for men and one for women: https://thinksteroids.com/community/posts/774168

Unsuccessful Novel Treatment Of Female Pattern Androgenetic Alopecia With Injected Bimatoprost (Latisse)
Michael Scally: Unsuccessful Novel Treatment Of Female Pattern Androgenetic Alopecia With Injected Bimatoprost (Latisse)

 

[Michael Scally MD]

US sales of Botox continue to increase
US sales of Botox continue to increase - FT.com

Sales of Botox continue to be robust in the US despite a sluggish economy, as ageing US citizens increasingly turn to the wrinkle-erasing medicine to preserve their youthful appearances.

David Pyott, chief executive of Allergan, told the Financial Times that during the depths of the recession in 2009, Botox users continued to stick with the product but used it less frequently. Typically, users receive a series of forehead injections every four months but the company noticed them spreading out treatments as unemployment rose and home prices fell.

Botox generates $1.3bn in annual sales and was first approved 21 years ago for the treatment of eye muscle twitches.

“During the recession, I used to say that for ladies, the face is the one outfit you wear every day,” Mr Pyott said. “Appearance is high on the list of priorities and people didn't stop unless they were in foreclosure or some dreadful circumstance.”

Botox sales are up 13 per cent so far this year compared with the same period a year ago. Meanwhile, sales of fillers, used to reduce creases around the mouth, and breast implants have also continued to be strong for Allergan.

The company attributes its prowess to the fact that users of its cosmetic products and procedures tend to earn more than $70,000, putting them in a demographic that tends to purchase luxury goods and be more recession-resistant.

But Mr Pyott stressed that Botox is much more than a facial fix, noting that it has 23 uses around the world and has been approved for seven medical conditions in the US. Last month, US health regulators approved Botox for the treatment of overactive bladders, and Allergan said it could be used to shrink prostates, relieve arthritis and alleviate an extreme constipation condition known as anal fissure.

Allergan is also stepping up its efforts to find a baldness treatment, which is seen by many analysts to be among the biggest prizes in pharmaceutical research.

Mr Pyott hopes that a medicine called Latisse could be its next Botox, and the company is using the same model of capitalising on unintended side-effects to help it evolve into a potential blockbuster drug.

Latisse was originally designed as a drug to treat glaucoma but patients realised it was lengthening their eyelashes. It was approved for that use three years ago, and now Mr Pyott has told his research team to speed up their efforts to determine if the medicine can successfully regrow eyebrows and scalp hair, as it has anecdotally been shown to do.

“If it works on male and female baldness, that’s a big deal,” Mr Pyott said.